O n December 3, 2012, a three judge panel of a U.S. appeals court took a controversial leap toward what some fear will be license by the courts to invalidate a host of state and federal regu lations, including some applica ble to health care. In recent years, the Supreme Court has broadened the reach of the First Amend ment, defining "protected speech" in such a way as to curtail or eliminate certain familiar govern mental restraints. (See table for an overview of cases related to commercial speech and the phar maceutical industry.) At issue in the December 3 opinion -which is doubtless headed for further appeal -were the Food and Drug Administration (FDA) regu lations applicable to marketing of prescription pharmaceuticals for offlabel uses. Overturning the conviction of a sales representa tive who was found to have en gaged in offlabel promotion of a prescription drug, a threejudge panel of the U.S. The FDA is vested with the re sponsibility of overseeing the safe ty of pharmaceutical production and the veracity of marketing. Its rigorous approval process requires that each new product be tested for safety and efficacy for each in tended use. Although FDA regu lations warn that it is considered "misbranding" for marketers to "recommend or suggest" that a drug is appropriate for an indica tion for which it has not specifi cally been approved, the FDA's authority does not extend to the practice of medicine, and thus it cannot prohibit physicians from prescribing approved drugs for nonapproved uses.
The Vermont law at issue in Sorrell permitted mining of physi cians' prescribing data from pa tient information for some pur poses (e.g., research), but not for others (primarily marketing), in order to advance the state's goal of limiting the promotion of ex pensive, brandname products. The Supreme Court held that a law that constrains speech on the ba sis of its content and its speaker must be reviewed for First Amendment purposes, applying a standard of "heightened" con stitutional scrutiny. Although it acknowledged the importance of Vermont's asserted interests in medical privacy and the reduction of health care costs, the Court nevertheless concluded that Ver mont's datamining prohibition unduly restricted free speech and was therefore unconstitutional.
At the heart of Sorrell was the question of whether governments are permitted to enact regula tions, even those protecting the health of the public, that single out a particular industry (e.g., the pharmaceutical industry) and allow some messages (e.g., pro moting brandname drugs for offlabel uses) but not others. As noted in the dissent, traditional regulatory programs do, in fact, target particular industries, and when they are narrowly tailored to advance significant state ob jectives, they have generally been upheld. The key to passing con stitutional scrutiny is whether the law at issue discriminates on the basis of the content of the message.
Disposing first of Vermont's argument that data mining in volves conduct rather than speech, Sorrell held that the creation and PERSPE C T I V E n engl j med 368;2 nejm.org january 10, 2013 104 distribution of information is in fact speech: "Facts, after all, are the beginning point for much of the speech that is most essential to advance human knowledge and to conduct human affairs." Applying First Amendment prin ciples, the Court found the Ver mont law to be discriminatory in that it suppressed a particularly effective, albeit distasteful, mes sage. The majority concluded, "If pharmaceutical marketing af fects treatment decisions, it does so because doctors find it persua sive," and "the fear that speech might persuade provides no law ful basis for quieting it."
Waiting in the First Amend ment wings, Caronia involved a sales representative of Orphan Medical, a subsidiary of Jazz Phar maceuticals, who was assigned to promote the prescription drug Xyrem (sodium oxybate), a cen tral nervous system depressant approved for the treatment of cataplexy and narcolepsy (includ ing daytime sleepiness) in adults. Xyrem is a Schedule III controlled substance known to be abused by young adults. It is used off label to treat children for cata plexy and narcolepsy and to treat adults for a variety of conditions, including fibromyalgia, schizo phrenia, chronic fatigue syn drome, and severe cluster head aches. Caronia and a physician from Orphan gave talks and met individually with prescribers to promote Xyrem, allegedly for offlabel uses. Suspecting that this illegal marketing was taking place, the Department of Justice conducted a sting operation, se cretly recording one such meet ing. Caronia and the physician were both indicted for offlabel drug promotion.
Challenging the constitution ality of the misbranding charges, Caronia argued that the govern ment cannot restrict truthful, non misleading commercial speech promoting the use of a pharma ceutical product, even offlabel. The trial court -a federal dis trict court in New York -found against Caronia, holding that "constraining the marketing op tions of manufacturers is one of the few mechanisms available to the FDA to ensure that manufac turers will not seek approval only for certain limited uses of drugs, then promote that same drug for offlabel uses, effectively circum venting the FDA's new drug re quirements." 4 Heeding a 2008 cautionary note from the Seventh Circuit that a "court should hesi tate before extending . . . [a] historical reading of the Consti tution in a way that injures the very audience that is supposed to benefit from free speech," 5 and concluding that it could not iden tify a less restrictive manner in which to prohibit pharmaceutical companies from circumventing the FDA approval process, the trial court in Caronia upheld the constitutionality of the FDA regu lations, concluding that "any right Caronia had as Xyrem's sales rep resentative to express as commer cial speech the truthful promo tion of Xyrem's offlabel uses is not unconstitutionally restricted by the misbranding provisions" 4 of the FDA.
In overturning Caronia's con 
